ClinicalTrials.gg
Not yet recruitingNCT07858357Updated Oct 5, 2026

Immersive Technology Headsets to Reduce Procedural Pain and Anxiety: Feasibility and Effects in Cutaneous Leishmaniasis Patients in Pakistan

An interventional study of Virtual Reality in Cutaneous Leishmaniasis, Pain and Anxiety, sponsored by Stanford University. Not yet recruiting. Open to participants aged 5 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Stanford University · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
5 Years to 99 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn whether immersive technology (virtual reality) headsets can reduce procedural pain and anxiety during diagnosis, intralesional and intramuscular injections, and wound/dressing care in pediatric patients 5 years of age and older and adult patients with cutaneous leishmaniasis receiving treatment at the MSF clinic in Peshawar, Khyber Pakhtunkhwa, Pakistan.

02

Conditions studied

  • Cutaneous Leishmaniasis
  • Pain
  • Anxiety

Keywords

  • Immersive Technology
03

In context

Leishmaniasis, Cutaneous

104 studies on the registry are indexed under Leishmaniasis, Cutaneous; 19 are open to participants now.

This study's planned enrollment of 15 is below the median of 60 across 77 interventional studies indexed under Leishmaniasis, Cutaneous.

Browse Leishmaniasis, Cutaneous studies →

Lead sponsor

Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.

Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric cutaneous leishmaniasis patients
  • Receiving cutaneous leishmaniasis care (diagnosis, treatment, and/or wound/lesion management) at the MSF cutaneous leishmaniasis facility in Peshawar

Exclusion criteria

Exclusion Criteria:

  • Legal guardian not present to obtain consent
  • Child with a significant neurological condition, or major developmental disability
  • A history of severe motion sickness
  • A history of seizures cause by flashing light
  • Major surgery within the last 48 hours
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Cutaneous leishmaniasis (CL) patient

    Behavioral: Virtual Reality

Interventions

  • BehavioralVirtual Reality

    Participants interact with virtual reality games designed for procedural distraction while receiving medical treatment. Following treatment completion, participants undergo brief surveys and a semi-structured interview.

06

What researchers measure

Primary outcomes

  1. Participant feasibility and acceptability regarding immersive technology

    Qualitative evaluation of participant attitudes, perceptions, and user experience with immersive technology headsets collected via semi-structured focus group interviews. Feedback will be categorized into core thematic domains including ease of use, comfort, and willingness to use in future care.

    Time frame: Immediately after intervention

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Oct 5, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07858357
Responsible party
Thomas Caruso (Clinical Professor, Stanford University) — Principal investigator
First posted
Oct 5, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Oct 5, 2026

Study contacts

Thomas Caruso, MD, PhD
Contact
tjcaruso@stanford.edu
6507235728
Man Yee Suen, MMedSc
Contact
smy822@stanford.edu
6507235728

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion